Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Rudolph Navari
Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: Approval and Efficacy
Cancer Management and Research
Oncology
Related publications
Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting
Malignant tumours
Efficacy of Triple Antiemetic Therapy (Palonosetron, Dexamethasone, Aprepitant) for Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Carboplatin-Based, Moderately Emetogenic Chemotherapy.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Real-World Effectiveness of Palonosetron-Based Antiemetic Regimens: Preventing Chemotherapy-Induced Nausea and Vomiting
Journal of Comparative Effectiveness Research
Health Policy
Palonosetron (Aloxi): A Second-Generation 5-Ht3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting
Baylor University Medical Center Proceedings
Medicine
Daily Palonosetron Is Superior to Ondansetron in the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Acute Myelogenous Leukemia
Cancer
Cancer Research
Oncology
Ramosetron Versus Palonosetron in Combination With Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Cancer Research and Treatment
Cancer Research
Oncology
Preventing Chemotherapy-Induced Nausea and Vomiting With Netupitant/Palonosetron, the First Fixed Combination Antiemetic: Current and Future Perspective
Future Oncology
Medicine
Cancer Research
Oncology
Corticosteroids in the Treatment of Chemotherapy-Induced Nausea and Vomiting
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Dronabinol for Chemotherapy-Induced Nausea and Vomiting Unresponsive to Antiemetics
Cancer Management and Research
Oncology
